2025 Impact Report : FOXG1 Research Foundation

2025 marked a pivotal year for the FOXG1 Research Foundation.

We successfully completed IND-enabling toxicology studies and submitted an Investigational New Drug (IND) application to the FDA, advancing the first-ever FOXG1 gene therapy toward patient clinical trials in 2026.

As a global, parent-led organization, we continue to demonstrate that families can independently drive rare disease drug development—executing clinical trials with rigor, urgency, and responsibility.

Alongside this progress, we expanded patient care, research, advocacy, and global awareness, while honoring the lives lost within our community and reaffirming why this work cannot wait.

Together with our families, donors, scientific partners, and clinicians, we are building a future where treatment is possible.